Pila Pharma starts enrollment for PP-CT04 Part 1 obesity trial of XEN-D0501

Pila Pharma initiated its first clinical site for PP-CT04, enabling enrollment to begin in Part 1 of a 12-week obesity trial testing oral TRPV1 antagonist XEN-D0501. Part 1 enrolls 8 participants to generate initial safety findings before Part 2 can start.